Review
Biochemistry & Molecular Biology
Amir R. Afshari, Ali Motamed-Sanaye, Hamed Sabri, Arash Soltani, Sepideh Karkon-Shayan, Sarvin Radvar, Hossein Javid, Hamid Mollazadeh, Thozhukat Sathyapalan, Amirhossein Sahebkar
Summary: The current standard of care for glioblastoma multiforme (GBM) is inadequate, with overall survival less than one year under current treatments. Understanding the molecular pathogenesis of GBM is crucial for future therapeutic approaches. The interaction between neurotransmitter substance P (SP) and its receptor NK-1R is proposed as a potential mechanism for treating GBM.
CURRENT MEDICINAL CHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Janine Suthiram, Ane Pieters, Zulfiah Mohamed Moosa, Jan Rijn Zeevaart, Mike M. Sathekge, Thomas Ebenhan, Ross C. Anderson, Claire L. Newton
Summary: Radiopharmaceutical development relies on the affinity and selectivity of the biological component for the intended target. A neuropeptide analogue, DOTA-[Thi(8),Met(O-2)(11)]SP, has shown promising results in the treatment of glioblastoma. However, modifications to the analogue that affect its selectivity for the neurokinin-1 receptor (NK1R) could limit its therapeutic potential. In this study, the receptor selectivity of DOTA-[Thi(8),Met(O-2)(11)]SP was examined, and it was found to have high potency and selectivity for NK1R.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Longfei Deng, Xuan Zhai, Ping Liang, Hongjuan Cui
Summary: TRAIL holds therapeutic potential in cancer treatment, but many cancers, including GBM, exhibit resistance. Recent studies have identified new mechanisms in regulating TRAIL-induced apoptosis in GBM and effective combinatorial strategies. The TRAIL/TRAIL death receptor axis may have future clinical applications for GBM treatment.
Article
Oncology
Chuntao Li, Bo Chen, Junxia Zhang, Jingxuan Yang, Muzi Guo, Yu Ren, Zhijun Zhou, Kar-Ming Fung, Min Li, Liyang Zhang, Zhixiong Liu
Summary: SEM1 is highly expressed in gliomas and correlated with malignant features and poor prognosis. SEM1 plays a critical role in the proliferation, apoptosis, invasion, and migration of glioma cells through regulating the PI3K-Akt pathway. The SEM1 malignant regulatory network shows significant importance for the prognosis and treatment of gliomas.
Article
Biochemistry & Molecular Biology
Ming Wang, Wenyan Zhang, Yibo Liu, Zhigang Ma, Wei Xiang, Yuqi Wen, Dingkun Zhang, Yanling Li, Yeming Li, Tao Li, Ligang Chen, Jie Zhou
Summary: The study reveals that PDIA4 plays a critical role in promoting glioblastoma (GBM). Downregulation of PDIA4 inhibits proliferation and promotes apoptosis of GBM cells, potentially through suppressing protein phosphorylation levels of the PI3K/AKT/mTOR pathway.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Oncology
Huikai Zhang, Yang Xu, Gang Deng, Fanen Yuan, Yinqiu Tan, Lun Gao, Qian Sun, Yangzhi Qi, Kun Yang, Rongxin Geng, Hongxiang Jiang, Baohui Liu, Qianxue Chen
Summary: The study demonstrates that SAA1 is up-regulated in GBM and its high expression indicates poor prognosis, promoting GBM cell death by regulating apoptosis. Gliomas with low SAA1 expression show increased sensitivity to TMZ, suggesting SAA1 as a regulator of cell apoptosis and a novel biomarker for glioma sensitivity to TMZ.
Article
Allergy
Mohna Bandyopadhyay, Adrian E. Morelli, Stephen C. Balmert, Nicole L. Ward, Geza Erdos, Tina L. Sumpter, Emrullah Korkmaz, Daniel H. Kaplan, Martin H. Oberbarnscheidt, Olga Tkacheva, William J. Shufesky, Louis D. Falo, Adriana T. Larregina
Summary: The study demonstrated the necessity of NK1R signaling in the development of contact dermatitis (CD) through substance P and hemokinin 1. Targeting NK1R in keratinocytes and dendritic cells prevented CD, while skin codelivery of hapten or Ag MNA inhibited neuropeptide-mediated skin inflammation and promoted regulatory T cells, preventing CD onset and relapses.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Ophthalmology
Romina Mayra Lasagni Vitar, Marco Barbariga, Philippe Fonteyne, Fabio Bignami, Paolo Rama, Giulio Ferrari
Summary: This study demonstrates that the NK1R antagonist fosaprepitant effectively reduces ocular surface nociception by decreasing SP release and leukocyte infiltration. Fosaprepitant repurposing shows promise for the treatment of ocular pain.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
(2021)
Article
Oncology
Jiajia Chen, Yuecan Zeng, Rong Wu, Ying Xuan, Min Jiang, Hao Teng
Summary: The study found that DUSP26 is down-regulated in high-grade gliomas and GBM compared to normal brain tissues. At the cellular level, DUSP26 overexpression resulted in decreased cell proliferation, migration, and senescence in U251 and U87 cells, with increased apoptosis. Additionally, the biological effects of DUSP26 overexpression were associated with the dephosphorylation of proteins in the MAPK and Akt signaling pathways.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Qingming Meng, Junbo Zhou, Fangting You, Yue Wu, Liquan Yang, Yan Wang, Xu Zhang, Shangfeng Gao, Rutong Yu, Xiaoxing Yin
Summary: AB38b shows dose- and time-dependent inhibition on cell proliferation in GBM cell lines, blocks cell cycle progression, induces early apoptosis, decreases AKT/mTOR pathway activity, and increases ROS generation. Treatment with antioxidants or overexpression of constitutively active AKT can reverse the effects of AB38b on GBM cells. Administration of AB38b inhibits tumor growth, decreases AKT/mTOR pathway activity, and prolongs survival in GBM animal models without adverse effects on major organs, suggesting it exerts anti-glioma activity through ROS generation and AKT/mTOR pathway inhibition.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Guoxiang Tong, Tianhao Peng, Ya Chen, Lijuan Sha, Huikang Dai, Yidong Xiang, Zhiqi Zou, Heli He, Sha Wang
Summary: Colorectal cancer is a common and deadly disease. Single drug therapy has limitations, while combination targeted drug therapy shows promise. This study focuses on the effects of the GLP-1 receptor agonist liraglutide on CRC cells and the PI3K/Akt/mTOR signaling pathway, aiming to find alternative treatments for CRC.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Medicinal
Xun Yang, Zeyuan Liu, Xu Xu, Meng He, Hongtao Xiong, Lijun Liu
Summary: Casticin has shown inhibitory effects on the growth of glioblastoma cells by inducing apoptosis and autophagy. It also reduces the population of glioblastoma stem cells. The mechanisms involve the inhibition of Akt/mTOR and JAK2/STAT3 signaling pathways.
PHYTOTHERAPY RESEARCH
(2023)
Review
Biochemistry & Molecular Biology
Fariba Kokabi, Safieh Ebrahimi, Farshad Mirzavi, Nazanin Ghiasi Nooghabi, Seyedeh Fatemeh Hashemi, Seyed Isaac Hashemy
Summary: Diabetes is the world's fastest-growing disease characterized by persistent hyperglycemia and chronic complications. Substance P and its receptor system have been found to be involved in diabetes pathogenesis and can have both destructive and protective effects on the disease. Understanding the functional relevance of this system in diabetes may lead to new therapeutic options for diabetes and its associated chronic conditions.
Article
Biochemistry & Molecular Biology
Viktor S. Kokhan, Petr K. Anokhin, Denis A. Abaimov, Inna Yu Shamakina, Vladislav O. Soldatov, Alexey Deykin
Summary: This study found that rolapitant, a neurokinin-1 receptor antagonist, can rapidly penetrate specific brain regions involved in anxiety and reward. It was also effective in reducing anxiety behavior and alcohol consumption following withdrawal. These findings suggest that rolapitant may be a potential treatment option for relapse prevention in alcohol-dependent patients.
Article
Biochemistry & Molecular Biology
Joanna Matalinska, Katarzyna Kosinska, Pawel K. Halik, Przemyslaw Kozminski, Piotr F. J. Lipinski, Ewa Gniazdowska, Aleksandra Misicka
Summary: Locoregionally administered, NK1 receptor (NK1R) targeted radionuclide therapy using NK1R antagonist as a radiopharmaceutical vector was investigated in this study. Structural modifications were made to evaluate the impact on NK1R binding, and the radioconjugates showed promising binding characteristics. However, limited stability was observed in human plasma. Further studies are needed for the molecular design of small molecular NK1R-targeting vectors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Patrick C. Gedeon, Teilo H. Schaller, Satish K. Chitneni, Bryan D. Choi, Chien-Tsun Kuan, Carter M. Suryadevara, David J. Snyder, Robert J. Schmittling, Scott E. Szafranski, Xiuyu Cui, Patrick N. Healy, James E. Herndon, Roger E. McLendon, Stephen T. Keir, Gary E. Archer, Elizabeth A. Reap, Luis Sanchez-Perez, Darell D. Bigner, John H. Sampson
CLINICAL CANCER RESEARCH
(2018)
Article
Clinical Neurology
Ahmet F. Atik, Carter M. Suryadevara, Ryan M. Schweller, Jennifer L. West, Patrick Healy, James E. Herndon, Kendra L. Congdon, Luis Sanchez-Perez, Roger E. McLendon, Gerald E. Archer, Peter Fecci, John H. Sampson
JOURNAL OF CLINICAL NEUROSCIENCE
(2018)
Review
Oncology
Bryan D. Choi, Marcela V. Maus, Carl H. June, John H. Sampson
CLINICAL CANCER RESEARCH
(2019)
Article
Oncology
Carter M. Suryadevara, Rupen Desai, S. Harrison Farber, Bryan D. Choi, Adam M. Swartz, Steven H. Shen, Patrick C. Gedeon, David J. Snyder, James E. Herndon, Patrick Healy, Elizabeth A. Reap, Gary E. Archer, Peter E. Fecci, John H. Sampson, Luis Sanchez-Perez
CLINICAL CANCER RESEARCH
(2019)
Correction
Biochemistry & Molecular Biology
Pakawat Chongsathidkiet, Christina Jackson, Shohei Koyama, Franziska Loebel, Xiuyu Cui, Harrison Farber, Karolina Woroniecka, Aladine A. Elsamadicy, Cosette A. Dechant, Hanna R. Kemeny, Luis Sanchez-Perez, Tooba A. Cheema, Nicholas C. Souders, James E. Herndon, Jean-Valery Coumans, Jeffrey I. Everitt, Brian V. Nahed, John H. Sampson, Michael D. Gunn, Robert L. Martuza, Glenn Dranoff, William T. Curry, Peter E. Fecci
Review
Pharmacology & Pharmacy
Kendra L. Congdon, Luis A. Sanchez-Perez, John H. Sampson
PHARMACOLOGY & THERAPEUTICS
(2019)
Review
Oncology
William Tomaszewski, Luis Sanchez-Perez, Thomas F. Gajewski, John H. Sampson
CLINICAL CANCER RESEARCH
(2019)
Review
Oncology
Kenneth Aldape, Kevin M. Brindle, Louis Chesler, Rajesh Chopra, Amar Gajjar, Mark R. Gilbert, Nicholas Gottardo, David H. Gutmann, Darren Hargrave, Eric C. Holland, David T. W. Jones, Johanna A. Joyce, Pamela Kearns, Mark W. Kieran, Ingo K. Mellinghoff, Melinda Merchant, Stefan M. Pfister, Steven M. Pollard, Vijay Ramaswamy, Jeremy N. Rich, Giles W. Robinson, David H. Rowitch, John H. Sampson, Michael D. Taylor, Paul Workman, Richard J. Gilbertson
NATURE REVIEWS CLINICAL ONCOLOGY
(2019)
Article
Oncology
Landon J. Hansen, Ran Sun, Rui Yang, Simranjit X. Singh, Lee H. Chen, Christopher J. Pirozzi, Casey J. Moure, Carlee Hemphill, Austin B. Carpenter, Patrick Healy, Ryan C. Ruger, Chin-Pu J. Chen, Paula K. Greer, Fangping Zhao, Ivan Spasojevic, Carole Grenier, Zhiqing Huang, Susan K. Murphy, Roger E. McLendon, Henry S. Friedman, Allan H. Friedman, James E. Herndonll, John H. Sampson, Stephen T. Keir, Darell D. Bigner, Hai Yan, Yiping He
Article
Biochemical Research Methods
Teilo H. Schaller, Matthew W. Foster, J. Will Thompson, Ivan Spasojevic, Deimante Normantaite, M. Arthur Moseley, Luis Sanchez-Perez, John H. Sampson
JOURNAL OF PROTEOME RESEARCH
(2019)
Letter
Oncology
Kenneth Aldape, Kevin M. Brindle, Louis Chesler, Rajesh Chopra, Amar Gajjar, Mark R. Gilbert, Nicholas Gottardo, David H. Gutmann, Darren Hargrave, Eric C. Holland, David T. W. Jones, Johanna A. Joyce, Pamela Kearns, Mark W. Kieran, Ingo K. Mellinghoff, Melinda Merchant, Stefan M. Pfister, Steven M. Pollard, Vijay Ramaswamy, Jeremy N. Rich, Giles W. Robinson, David H. Rowitch, John H. Sampson, Michael D. Taylor, Paul Workman, Richard J. Gilbertson
NATURE REVIEWS CLINICAL ONCOLOGY
(2019)
Review
Clinical Neurology
Peter E. Fecci, John H. Sampson
JOURNAL OF NEUROSURGERY
(2019)
Review
Oncology
Kelly M. Hotchkiss, John H. Sampson
Summary: GBM is difficult to eradicate with immunotherapy and chemotherapy, and different doses and timing of chemotherapy may affect tumor eradication efficacy.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Yaoying Wu, Hanning Wen, Zachary J. Bernstein, Kelly M. Hainline, Tykia S. Blakney, Kendra L. Congdon, David J. Snyder, John H. Sampson, Luis Sanchez-Perez, Joel H. Collier
Summary: The study demonstrates the potential clinical benefit of vaccine-induced antibody responses for tumor treatments when combined with simultaneous CD8(+) and CD4(+) responses, using a nanofiber vaccine design approach. Additionally, the study highlights the importance of supramolecular nanomaterials in developing multiepitope cancer vaccines.
Review
Oncology
John H. Sampson, Michael D. Gunn, Peter E. Fecci, David M. Ashley
NATURE REVIEWS CANCER
(2020)
Article
Biochemistry & Molecular Biology
Pei-Yang Gao, Ya-Nan Ou, Yi-Ming Huang, Zhi-Bo Wang, Yan Fu, Ya-Hui Ma, Qiong-Yao Li, Li-Yun Ma, Rui-Ping Cui, Yin-Chu Mi, Lan Tan, Jin-Tai Yu
Summary: Liver function may play a role in the progression of Alzheimer's disease. The study found that as AD progressed, certain liver function markers increased while others decreased. The relationship between liver function and CSF AD biomarkers indicates a potential mediation effect on cognition.
JOURNAL OF NEUROCHEMISTRY
(2024)